BioSpace News Archive

DarioHealth today announced it has successfully sold the first Lightning-enabled version of the acclaimed Dario Blood Glucose Monitoring System in the United Kingdom, according to schedule.

The new series also provides low cost per sample for small and large projects across multiple research applications.

Thermo Fisher Scientific has expanded its Oncomine portfolio with new assays for liquid biopsy and immuno-oncology to complement its comprehensive solutions for clinical research.

Lunatic’s new IgG Quant app hits the upper analysis range needed to measure these protein drugs, and does it with only 2 µL of sample straight up - no dilution needed.

If approved in Europe, EVENITY will be a novel osteoporosis treatment that increases bone formation and reduces bone resorption simultaneously to increase BMD and reduce the risk of fracture.

QIAGEN has set a goal to exceed $140 million in 2018 sales from this portfolio, up from over $115 million in 2017.

Revenue from biopharmaceutical companies is expected to be approximately $33.4 million in the fourth quarter of 2017 and approximately $99.7 million for the full year ended December 31, 2017, compared to $19.0 million and $78.8 million in the fourth quarter and full year ended December 31, 2016, respectively.

The FDA has set a PDUFA date of July 6, 2018.

Financing will fund the commercial launch of Intuity Medical’s POGO Automatic Blood Glucose Monitoring System.

Juniper Pharma today announced the extension of its supply agreement for CRINONE with an affiliate of Merck KGaA, Darmstadt, Germany.